本帖最后由 老马 于 2013-3-13 13:43 编辑
; f- o# i' b* a6 E' k- V0 }# @! M, L9 t$ s7 ?5 ~
健择(吉西他滨)+顺铂+阿瓦斯汀2 p! J+ y( Q ^, C
Gemzar +Cisplatin + Avastin# {# i( n) J) n1 `. R- l8 `
http://annonc.oxfordjournals.org/content/21/9/1804.full8 ]. I# W+ V$ R; M. f- S: N
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
, Y$ A! r5 p$ u# a7 M% i$ B& H9 wPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. " [8 \3 M A$ ~7 W" {
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. $ t ^: l% M: d4 Q5 t
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 835)
) }. U* [ l" \6 H# i. e" Q华为网盘附件:( O) p7 J: J( ?
【华为网盘】ava.JPG. [# U" L& n( Y2 Q$ W
|